{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:57:31Z","timestamp":1792036651932,"version":"4.4.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008126","name":"Dana-Farber\/Harvard Cancer Center","doi-asserted-by":"publisher","award":["NIH 5 P30 CA06516"],"award-info":[{"award-number":["NIH 5 P30 CA06516"]}],"id":[{"id":"10.13039\/100008126","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-12-1-0155"],"award-info":[{"award-number":["W81XWH-12-1-0155"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Prospective data on maintenance therapy with bevacizumab for persons with NF2-related schwannomatosis (NF2-SWN) is lacking. In this prospective multicenter phase II study, we evaluated the efficacy, safety, and tolerability of bevacizumab for maintenance therapy in children and adults with NF2-SWN and hearing loss due to vestibular schwannomas (VS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Following induction therapy, participants received bevacizumab 5 mg\/kg every 3 weeks for 18 months. Participants were monitored for changes in hearing, tumor size, and quality of life (QOL), and for adverse events. Hearing loss was defined as a statistically significant decline in word recognition score (WRS) or pure-tone average compared to the study baseline; tumor growth was defined as &amp;gt;20% increase in volume compared to baseline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty participants with NF2-SWN (median age 23.5 years; range, 12.5\u201362.5 years) with hearing loss in the target ear (median WRS 70%, range 2%\u201394%) received maintenance bevacizumab. Freedom from hearing loss in the target ear was 95% after 48 weeks, 89% after 72 weeks, and 70% after 98 weeks. Freedom from tumor growth in the target VS was 94% after 48 weeks, 89% after 72 weeks, and 89% after 98 weeks. NF2-related QOL remained stable for 98 weeks whereas tinnitus-related distress decreased. Maintenance bevacizumab was well tolerated, with 3 participants (15%) discontinuing treatment due to adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Maintenance bevacizumab (5 mg\/kg every 3 weeks) is associated with high rates of hearing and tumor stability during 18 months of follow-up. No new unexpected adverse events related to bevacizumab were identified in this population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/neuonc\/noad066","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T15:31:56Z","timestamp":1680535916000},"page":"1498-1506","source":"Crossref","is-referenced-by-count":41,"title":["Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with <i>NF2<\/i>-related schwannomatosis and progressive vestibular schwannoma"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6109-6419","authenticated-orcid":false,"given":"Scott R","family":"Plotkin","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital and Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Allen","sequence":"additional","affiliation":[{"name":"NYU Langone Health , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4918-0167","authenticated-orcid":false,"given":"Girish","family":"Dhall","sequence":"additional","affiliation":[{"name":"University of Southern California , Los Angeles, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian L","family":"Campian","sequence":"additional","affiliation":[{"name":"Washington University , St. Louis, Missouri , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9465-0917","authenticated-orcid":false,"given":"D Wade","family":"Clapp","sequence":"additional","affiliation":[{"name":"University of Indiana , Indianapolis, Indiana , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Fisher","sequence":"additional","affiliation":[{"name":"The Children\u2019s Hospital of Philadelphia , Philadelphia, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh K","family":"Jain","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital and Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6678-6884","authenticated-orcid":false,"given":"James","family":"Tonsgard","sequence":"additional","affiliation":[{"name":"University of Chicago , Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5623-3362","authenticated-orcid":false,"given":"Nicole J","family":"Ullrich","sequence":"additional","affiliation":[{"name":"Boston Children\u2019s Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coretta","family":"Thomas","sequence":"additional","affiliation":[{"name":"University of Alabama , Birmingham, Alabama , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7788-4575","authenticated-orcid":false,"given":"Lloyd J","family":"Edwards","sequence":"additional","affiliation":[{"name":"University of Alabama , Birmingham, Alabama , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8272-339X","authenticated-orcid":false,"given":"Bruce","family":"Korf","sequence":"additional","affiliation":[{"name":"University of Alabama , Birmingham, Alabama , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9413-7531","authenticated-orcid":false,"given":"Roger","family":"Packer","sequence":"additional","affiliation":[{"name":"Children\u2019s National Medical Center , Washington, District of Columbia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7151-6528","authenticated-orcid":false,"given":"Matthias A","family":"Karajannis","sequence":"additional","affiliation":[{"name":"NYU Langone Health , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1049-0993","authenticated-orcid":false,"given":"Jaishri O","family":"Blakeley","sequence":"additional","affiliation":[{"name":"Johns Hopkins University , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"issue":"9","key":"2023080310451580800_CIT0001","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.gim.2022.05.007","article-title":"Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation","volume":"24","author":"Plotkin","year":"2022","journal-title":"Genet Med."},{"issue":"9679","key":"2023080310451580800_CIT0002","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/S0140-6736(09)60259-2","article-title":"Neurofibromatosis type 2","volume":"373","author":"Asthagiri","year":"2009","journal-title":"Lancet."},{"key":"2023080310451580800_CIT0003","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/MAO.0000000000000239","article-title":"Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients","volume":"35","author":"Plotkin","year":"2014","journal-title":"Otol Neurotol."},{"key":"2023080310451580800_CIT0004","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"N Engl J Med."},{"issue":"14","key":"2023080310451580800_CIT0005","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1200\/JCO.2015.64.3817","article-title":"Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-associated vestibular schwannomas","volume":"34","author":"Blakeley","year":"2016","journal-title":"J Clin Oncol."},{"issue":"6","key":"2023080310451580800_CIT0006","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.5301\/tj.5000313","article-title":"Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage","volume":"101","author":"Sponghini","year":"2015","journal-title":"Tumori."},{"key":"2023080310451580800_CIT0007","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-015-1828-8","article-title":"Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2","volume":"124","author":"Hochart","year":"2015","journal-title":"J Neurooncol."},{"key":"2023080310451580800_CIT0008","first-page":"281","article-title":"Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation","volume":"3","author":"Morris","year":"2016","journal-title":"Neurooncol Pract."},{"key":"2023080310451580800_CIT0009","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/neuonc\/nop010","article-title":"Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2","volume":"12","author":"Mautner","year":"2010","journal-title":"Neuro Oncol."},{"issue":"3","key":"2023080310451580800_CIT0010","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.critrevonc.2015.01.012","article-title":"Bevacizumab: a dose review","volume":"94","author":"Falk","year":"2015","journal-title":"Crit Rev Oncol Hematol."},{"issue":"35","key":"2023080310451580800_CIT0011","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1200\/JCO.19.01367","article-title":"Multicenter, prospective, phase II and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma","volume":"37","author":"Plotkin","year":"2019","journal-title":"J Clin Oncol."},{"key":"2023080310451580800_CIT0012","first-page":"603","article-title":"A clinical study of type 2 neurofibromatosis","volume":"84","author":"Evans","year":"1992","journal-title":"Q.J Med."},{"issue":"11","key":"2023080310451580800_CIT0013","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1212\/01.WNL.0000035638.74084.F4","article-title":"Evaluation of clinical diagnostic criteria for neurofibromatosis 2","volume":"59","author":"Baser","year":"2002","journal-title":"Neurology."},{"issue":"1","key":"2023080310451580800_CIT0014","doi-asserted-by":"crossref","first-page":"39","DOI":"10.7326\/0003-4819-113-1-39","article-title":"NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update","volume":"113","author":"Mulvihill","year":"1990","journal-title":"Ann Intern Med."},{"key":"2023080310451580800_CIT0015","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00129492-200601000-00020","article-title":"Using audiometric thresholds and word recognition in a treatment study","volume":"27","author":"Halpin","year":"2006","journal-title":"Otol Neurotol."},{"key":"2023080310451580800_CIT0016","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1044\/jshr.2103.507","article-title":"Speech-discrimination scores modeled as a binomial variable","volume":"21","author":"Thornton","year":"1978","journal-title":"J Speech Hear Res."},{"issue":"21 Suppl 1","key":"2023080310451580800_CIT0017","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1212\/01.wnl.0000435746.02780.f6","article-title":"Hearing and facial function outcomes for neurofibromatosis 2 clinical trials","volume":"81","author":"Plotkin","year":"2013","journal-title":"Neurology."},{"issue":"6","key":"2023080310451580800_CIT0018","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1227\/01.NEU.0000316858.25606.8F","article-title":"Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II","volume":"62","author":"Harris","year":"2008","journal-title":"Neurosurgery."},{"issue":"1","key":"2023080310451580800_CIT0019","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12955-017-0607-y","article-title":"Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality of Life (INF1-QOL) questionnaire","volume":"15","author":"Ferner","year":"2017","journal-title":"Health Qual Life Outcomes."},{"key":"2023080310451580800_CIT0020","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/MAO.0000000000001781","article-title":"Improvement in patient-reported hearing after treatment with bevacizumab in people with neurofibromatosis type 2","volume":"39","author":"Huang","year":"2018","journal-title":"Otol Neurotol."},{"issue":"1","key":"2023080310451580800_CIT0021","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/neuonc\/noz153","article-title":"EANO guideline on the diagnosis and treatment of vestibular schwannoma","volume":"22","author":"Goldbrunner","year":"2020","journal-title":"Neuro Oncol."},{"issue":"17","key":"2023080310451580800_CIT0022","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers","volume":"31","author":"Jain","year":"2013","journal-title":"J Clin Oncol."},{"issue":"5","key":"2023080310451580800_CIT0023","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell."},{"issue":"12","key":"2023080310451580800_CIT0024","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1007\/s00405-015-3604-y","article-title":"Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2","volume":"272","author":"Farschtschi","year":"2015","journal-title":"Eur Arch Otorhinolaryngol."},{"issue":"5","key":"2023080310451580800_CIT0025","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1055\/s-0038-1676628","article-title":"Long-term effects of bevacizumab on vestibular schwannoma volume in neurofibromatosis type 2 patients","volume":"80","author":"Killeen","year":"2019","journal-title":"J Neurol Surg B Skull Base."},{"issue":"5","key":"2023080310451580800_CIT0026","doi-asserted-by":"crossref","first-page":"e28228","DOI":"10.1002\/pbc.28228","article-title":"Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence","volume":"67","author":"Renzi","year":"2020","journal-title":"Pediatr Blood Cancer."},{"issue":"7","key":"2023080310451580800_CIT0027","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/neuonc\/noaa284","article-title":"Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution","volume":"23","author":"Forde","year":"2020","journal-title":"Neuro Oncol."},{"issue":"6","key":"2023080310451580800_CIT0028","doi-asserted-by":"crossref","first-page":"103148","DOI":"10.1016\/j.amjoto.2021.103148","article-title":"Reliability and toxicity of bevacizumab for neurofibromatosis type 2-related vestibular schwannomas: a systematic review and meta-analysis","volume":"42","author":"Shi","year":"2021","journal-title":"Am J Otolaryngol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noad066\/50432027\/noad066.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/25\/8\/1498\/51031031\/noad066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/25\/8\/1498\/51031031\/noad066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T10:46:21Z","timestamp":1691059581000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/25\/8\/1498\/7100416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,3]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4,3]]},"published-print":{"date-parts":[[2023,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noad066","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,4,3]]}}}